{
    "root": "c7f89286-2e38-4f6c-b70b-937c088f24ef",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Cyclobenzaprine hydrochloride",
    "value": "20250312",
    "ingredients": [
        {
            "name": "CYCLOBENZAPRINE HYDROCHLORIDE",
            "code": "0VE05JYS2P"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "HYPROMELLOSE 2910 (15 MPA.S)",
            "code": "36SFW2JZ0W"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 102",
            "code": "PNR0YF693Y"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        }
    ],
    "indications": "cyclobenzaprine hydrochloride tablets , usp indicated adjunct rest physical therapy relief muscle spasm associated acute , painful musculoskeletal conditions . improvement manifested relief muscle spasm associated signs symptoms , namely , pain , tenderness , limitation motion , restriction activities daily living . cyclobenzaprine hydrochloride tablets , usp used short periods ( two three weeks ) adequate evidence effectiveness prolonged available muscle spasm associated acute , painful musculoskeletal conditions generally short duration therapy longer periods seldom warranted . cyclobenzaprine hydrochloride tablets , usp found effective treatment spasticity associated cerebral spinal cord disease , children cerebral palsy .",
    "contraindications": "patients , recommended dose cyclobenzaprine hydrochloride tablets , usp 5 mg three times day . based individual patient response , dose may increased 10 mg three times day . cyclobenzaprine hydrochloride tablets , usp periods longer two three weeks recommended . ( ) . less frequent dosing considered hepatically impaired elderly patients ( , ) .",
    "warningsAndPrecautions": "cyclobenzaprine hydrochloride tablets , usp available 5 mg 7.5 mg 10 mg strengths . cyclobenzaprine hydrochloride tablets , usp 5 mg white off-white , film coated , round shaped , biconvex tablets , debossed `` u `` one side `` 1 `` side . bottles 20 : ndc 68788-8706-2 bottles 30 : ndc 68788-8706-3 bottles 60 : ndc 68788-8706-6 bottles 90 : ndc 68788-8706-9 bottles 120 : ndc 68788-8706-8",
    "adverseReactions": "hypersensitivity component product . concomitant monoamine oxidase ( mao ) inhibitors within 14 days discontinuation . hyperpyretic crisis seizures , deaths occurred patients receiving cyclobenzaprine ( structurally similar tricyclic antidepressants ) concomitantly mao inhibitor drugs . acute recovery phase myocardial infarction , patients arrhythmias , heart block conduction disturbances , congestive heart failure . hyperthyroidism .",
    "indications_original": "Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.\n                  Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living.\n                  \n                     Cyclobenzaprine hydrochloride tablets, USP should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted.\n                  \n                  Cyclobenzaprine hydrochloride tablets, USP has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy.",
    "contraindications_original": "For most patients, the recommended dose of cyclobenzaprine hydrochloride tablets, USP is 5 mg three times a day. Based on individual patient response, the dose may be increased to 10 mg three times a day. Use of cyclobenzaprine hydrochloride tablets, USP for periods longer than two or three weeks is not recommended. (see ).\n                  Less frequent dosing should be considered for hepatically impaired or elderly patients (see , and ).",
    "warningsAndPrecautions_original": "Cyclobenzaprine hydrochloride tablets, USP are available in 5 mg 7.5 mg and 10 mg dosage strengths. \n                  Cyclobenzaprine hydrochloride tablets, USP 5 mg are white to off-white, film coated, round shaped, biconvex tablets, debossed with \"U\" on one side and \"1\" on other side.\n                  Bottles of 20: NDC 68788-8706-2\n                  Bottles of 30: NDC 68788-8706-3\n                  Bottles of 60: NDC 68788-8706-6\n                  Bottles of 90: NDC 68788-8706-9\n                  Bottles of 120: NDC 68788-8706-8",
    "adverseReactions_original": "Hypersensitivity to any component of this product.\n                  Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation. Hyperpyretic crisis seizures, and deaths have occurred in patients receiving cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitor drugs.\n                  Acute recovery phase of myocardial infarction, and patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure.\n                  Hyperthyroidism."
}